Bemdaneprocel by BlueRock Therapeutics (Bayer): status and timeline

Milestones

Next · exPDite-2 primary endpoint readout

Phase I data showing safety and early efficacy2024Complete.
exPDite-2 Phase III trial enrollment beginsJun 2025Complete.

Most important updates

BlueRock announces first patient enrolled in exPDite-2 Phase III trialSep 2025

Upcoming

Mar 2027exPDite-2 primary endpoint readoutin about 20 weeks (next)

Current obstacles

Surgical accuracy and cell survivalPrecise implantation into small brain regions is technically demanding; high survival post-transplant challenging.
Clinical efficacy demonstrationExPDite-2 must show statistically significant motor improvement at week 78 to advance development.

Physics limits

Dopaminergic system complexityThe dopaminergic system spans multiple brain regions. Replacing neurons in striatum alone may not fully restore complex motor and cognitive functions lost to Parkinson's.
Immune tolerance in allogeneic transplantsEven without HLA matching, recipient brain mounts immune response to foreign cells, potentially limiting long-term survival.

How it works

3 parts

Cell differentiation

Pluripotent stem cells become dopamine neurons

Allogeneic pluripotent cells differentiate into dopaminergic neuron precursors through a defined pathway.

Transplantation

Surgical implantation into the brain

Neuron precursors surgically implanted into the striatum, the region most affected by dopaminergic loss.

Maturation and integration

Transplanted cells mature in situ

Over weeks and months, implanted cells mature into functional neurons and integrate into neural circuits.

Spec sheet

Spec	Bemdaneprocel
exPDite-2 planned enrollment	~102 patients^R (reported)

^R reported by the company

Update log

1 update

Sep 2025

Major: BlueRock announces first patient enrolled in exPDite-2 Phase III trialPressTest

About BlueRock Therapeutics (Bayer)

The team behind Bemdaneprocel

BlueRock Therapeutics (Bayer)

Stem cell therapy, cell therapy

Clinical-stage cell therapy company developing allogeneic dopaminergic neuron therapies. Founded 2016, acquired by Bayer 2019. Headquartered Cambridge, Massachusetts.

Bemdaneprocel is the first pluripotent stem cell-derived dopaminergic therapy in Phase III trials for Parkinson's.
ExPDite-2 is a randomized trial of ~102 patients with target completion March 2027.

bluerocktx.com (opens bluerocktx.com)Company profile →

Founded: 201610 yrs
Headquarters: United States
Status: Subsidiaryof Bayer AG
Valuation: Bayer AG-owned
Works in: BiotechCell & organ therapies
Coverage: 1 program · 1 updatelatest 1 Sep 2025checked 11 Oct
Acquired by: Bayer AG (opens bayer.com)

Spec

Bemdaneprocel

exPDite-2 planned enrollment

~102 patients^R (reported)